Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Unregistered Sales of Equity Securities. The disclosure set forth above in

Entry into a Material Definitive Agreement. On October 7, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company agreed to issue to Peak One, in a private placement offering (the “Offering”) upon the satisfaction of certain conditions specified in the SPA, a convertible debenture in the principal amount of $1,200,000 (the “Debenture”) and 125,000 restricted shares (the…

Regulation FD Disclosure. On September 17, 2026, the Company issued a press release announcing the closing of a private placement with Hamid Khoja, Ph.D., the Company’s Chief Scientific Officer. A copy of the press release is furnished as Exhibit 99.1 hereto. On September 18, 2026, the Company posted a presentation (the “Presentation”) to its website at www.fibrobiologics.com under “Presentations” in the “News & Events” subsection of the “Investor Relations” tab. The information set forth in…

Based in part upon the representations of the Purchaser in the SPA, the offer and sale of the securities to be issued in the Offering are being offered and sold pursuant to the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506(b) of Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United S…

Entry into a Material Definitive Agreement. On September 15, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Hamid Khoja, Ph.D., the Company’s Chief Scientific Officer (the “Purchaser”), relating to the issuance and sale of 298,508 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the “Warrants”), in a private placement (th…

Director — Leigh Steinberg: The filing discloses the appointment of a new non-employee director, which is a routine board composition change rather than an executive departure.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 22, 2026, FibroBiologics, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq Staff had determined to delist the Company’s securities from The Nasdaq Capital Market. The Staff Determination stated that the bid price of the Company’s l…

Director — Matt Link: Matt Link resigned from the Board of Directors.

Unregistered Sales of Equity Securities. The disclosure set forth above in

Entry into a Material Definitive Agreement. On June 25, 2026, FibroBiologics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Purchaser”) for a private placement offering (the “Offering”), pursuant to which the Company received gross proceeds of $3,000,000, before deducting placement agent fees and other offering expenses, in consideration of (i) pre-funded warrants in lieu of shares (the “Shares”) of th…

The filing describes the approval of a new equity and incentive compensation plan, which is not directly related to management changes.

Entry into a Material Definitive Agreement. As previously disclosed, on May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into that certain At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell shares of its common stock, par value $0.00001 per share (the “Common Stock”) from time to time through or to the Sales Agent (the “ATM Offering”). The shares of Common Stock to be sold under the S…

The filing describes the grant of stock options to certain officers, which is a routine compensatory arrangement.

Entry into a Material Definitive Agreement. On May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $6,150,000 from time to time through or to the Sales Agent (the “ATM Offering”). The…

Entry into a Material Definitive Agreement. On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd,…

Termination of a Material Definitive Agreement. The information set forth in

Entry into a Material Definitive Agreement. On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd,…

of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in

Entry into a Material Definitive Agreement. On March 31, 2026, FibroBiologics, Inc. (the “Company”) commenced a best-efforts public offering (the “Offering”) of (i) 1,028,788 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), (ii) pre-funded warrants in lieu of Shares to purchase up to 1,243,940 shares of Common Stock (“Pre-Funded Warrants”), and (iii) warrants to purchase one share of its Common Stock for each Share of Common Stock and/or…

The filing pertains to a compensation adjustment for the CFO, not a management change.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 4, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its market value of listed securities (“MVLS”) had closed below the minimum $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listin…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market un…

Entry into a Material Definitive Agreement. On December 14, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The p…

Unregistered Sales of Equity Securities. The disclosure set forth above in